CMS coverage guidance draws medtech, drug industry concerns

01/31/2013 | Bloomberg BNA (free content)

Draft guidance released by CMS in November on the use of coverage with evidence development (CED) for determining Medicare coverage elicited industry concerns. The guidance suggests available data used to obtain FDA OKs "will rarely be sufficient for Medicare coverage," creating more confusion on the use of CED, said Chandra Branham of the Advanced Medical Technology Association.

View Full Article in:

Bloomberg BNA (free content)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL